Nektar Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Nektar Therapeutics
NKTR Stock  USD 0.88  0.03  3.30%   
Nektar Therapeutics financial statements provide useful quarterly and yearly information to potential Nektar Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Nektar Therapeutics financial statements helps investors assess Nektar Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Nektar Therapeutics' valuation are summarized below:
Gross Profit
67.7 M
Profit Margin
(1.21)
Market Capitalization
167.7 M
Enterprise Value Revenue
0.3134
Revenue
98.4 M
There are over one hundred nineteen available fundamental ratios for Nektar Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to check Nektar Therapeutics' last-minute fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 03/19/2025, Enterprise Value is likely to grow to about 579.9 M, while Market Cap is likely to drop slightly above 91.8 M.

Nektar Therapeutics Total Revenue

160.52 Million

Check Nektar Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nektar Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 17.6 M, Interest Expense of 24.1 M or Total Revenue of 160.5 M, as well as many indicators such as Price To Sales Ratio of 1.85, Dividend Yield of 0.0 or PTB Ratio of 2.99. Nektar financial statements analysis is a perfect complement when working with Nektar Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Nektar Therapeutics Correlation against competitors.
To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.

Nektar Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets288.7 M303.9 M753.9 M
Pretty Stable
Short and Long Term Debt Total97.4 M102.6 M184.3 M
Very volatile
Other Current Liabilities26.2 M30 M28.8 M
Pretty Stable
Total Current Liabilities87.4 M61.4 M100.8 M
Very volatile
Property Plant And Equipment Net11.2 M11.8 M77 M
Very volatile
Accounts Payable8.4 M11.6 M8 M
Slightly volatile
Cash70.8 M44.3 M61 M
Slightly volatile
Non Current Assets Total40.4 M42.6 M226.7 M
Very volatile
Non Currrent Assets Other8.4 M16.9 M7.7 M
Pretty Stable
Cash And Short Term Investments432.8 M255.2 M496.9 M
Slightly volatile
Common Stock Shares Outstanding112.8 M205.7 M145.2 M
Slightly volatile
Liabilities And Stockholders Equity288.7 M303.9 M753.9 M
Pretty Stable
Non Current Liabilities Total298.4 M181.7 M295 M
Very volatile
Other Current Assets5.8 M6.1 M15 M
Pretty Stable
Other Stockholder Equity3.8 B3.7 B2.6 B
Slightly volatile
Total Liabilities385.8 M243.1 M395.8 M
Very volatile
Property Plant And Equipment Gross101.3 M142.3 M96.2 M
Slightly volatile
Total Current Assets470.3 M261.3 M541 M
Slightly volatile
Short Term Debt36.1 M19.9 M52.7 M
Pretty Stable
Common Stock Total Equity16.2 K17.1 K8.5 M
Slightly volatile
Short Term Investments400.8 M211 M443.6 M
Slightly volatile
Common Stock16.2 K17.1 K8.5 M
Slightly volatile
Net Receivables2.5 M2.6 M13.4 M
Pretty Stable
Other Liabilities105.7 M187.4 M137.4 M
Slightly volatile
Other Assets2.5 M2.6 M23.5 M
Very volatile
Long Term Debt200.4 M222.3 M209 M
Slightly volatile
Property Plant Equipment77.9 M77.3 M78.8 M
Pretty Stable
Inventory13.3 M18.5 M13.5 M
Slightly volatile
Intangible Assets23 M24.2 M56.1 M
Slightly volatile
Long Term Debt Total191.7 M284 M195 M
Slightly volatile
Capital Surpluse2.6 B4 B2.6 B
Slightly volatile
Capital Lease Obligations74 M135.4 M79.6 M
Slightly volatile
Deferred Long Term Liabilities16.3 M17.1 M47.6 M
Slightly volatile
Non Current Liabilities Other150.7 M134.8 M129.6 M
Slightly volatile
Short and Long Term Debt246.1 M286 M214.3 M
Slightly volatile
Net Invested Capital112 M117.9 M547.9 M
Very volatile
Net Working Capital238.9 M251.5 M473.1 M
Pretty Stable
Capital Stock20 K21.9 K17.9 K
Slightly volatile

Nektar Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization17.6 M9 M15.2 M
Pretty Stable
Total Revenue160.5 M98.4 M200.7 M
Very volatile
Gross Profit132.2 M98.4 M176.3 M
Very volatile
Other Operating Expenses256.9 M203.6 M310.1 M
Slightly volatile
Total Operating Expenses228.4 M197.7 M285.3 M
Slightly volatile
Research Development182.9 M120.9 M222.3 M
Slightly volatile
Selling General Administrative53.6 M76.8 M63.8 M
Slightly volatile
Non Recurring13.6 M18.4 M13.3 M
Slightly volatile
Tax Provision3.6 M3.4 M1.3 M
Slightly volatile
Interest Income15.4 M15.9 M24.4 M
Slightly volatile
Reconciled Depreciation10.2 M8.4 M13.2 M
Slightly volatile
Selling And Marketing Expenses1.8 M2 M2.2 M
Slightly volatile

Nektar Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow66.7 M35.3 M58.6 M
Slightly volatile
Capital Expenditures1.4 M1.5 M8.5 M
Pretty Stable
End Period Cash Flow70.8 M44.3 M61 M
Slightly volatile
Stock Based Compensation30.8 M21.6 M42 M
Slightly volatile
Change To Netincome50.1 M58.3 M45.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.851.943213.3413
Slightly volatile
Days Sales Outstanding7.88.2131.4726
Pretty Stable
Stock Based Compensation To Revenue0.170.21960.3073
Slightly volatile
EV To Sales2.412.535713.885
Slightly volatile
Inventory Turnover3.212.622.1407
Pretty Stable
Days Of Inventory On Hand141144191
Very volatile
Sales General And Administrative To Revenue0.820.77980.5706
Slightly volatile
Research And Ddevelopement To Revenue1.261.22841.7508
Very volatile
Capex To Revenue0.01420.01490.1139
Slightly volatile
Cash Per Share1.181.2412.9997
Pretty Stable
Income Quality1.551.4770.973
Pretty Stable
Intangibles To Total Assets0.150.120.1234
Slightly volatile
Current Ratio7.234.25566.675
Pretty Stable
Receivables Turnover37.8236.0226.6502
Very volatile
Capex Per Share0.00680.00710.0624
Slightly volatile
Revenue Per Share0.450.47861.2397
Very volatile
Interest Debt Per Share0.340.3621.3243
Slightly volatile
Debt To Assets0.260.33750.2712
Pretty Stable
Graham Number22.7925.6427.9539
Slightly volatile
Operating Cycle158153206
Slightly volatile
Ebt Per Ebit0.991.13311.4694
Pretty Stable
Long Term Debt To Capitalization0.450.520.7312
Pretty Stable
Total Debt To Capitalization0.430.62810.6303
Slightly volatile
Quick Ratio7.114.25566.5278
Pretty Stable
Net Income Per E B T0.740.9980.9887
Slightly volatile
Cash Ratio0.680.72071.1459
Slightly volatile
Days Of Inventory Outstanding141144191
Very volatile
Days Of Sales Outstanding7.88.2131.4726
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.281.00841.0908
Slightly volatile
Fixed Asset Turnover8.748.32434.1918
Pretty Stable
Debt Ratio0.260.33750.2712
Pretty Stable
Price Sales Ratio1.851.943213.3413
Slightly volatile
Asset Turnover0.180.32390.2622
Very volatile
Gross Profit Margin0.90.680.8214
Slightly volatile

Nektar Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap91.8 M96.6 M822.8 M
Slightly volatile
Enterprise Value579.9 M419.6 M982.4 M
Slightly volatile

Nektar Fundamental Market Drivers

Cash And Short Term Investments255.2 M

Nektar Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Nektar Therapeutics Financial Statements

Nektar Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Nektar Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Nektar Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Nektar Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-7.4 M-7 M
Total Revenue98.4 M160.5 M
Cost Of Revenue33 M26.8 M
Stock Based Compensation To Revenue 0.22  0.17 
Sales General And Administrative To Revenue 0.78  0.82 
Research And Ddevelopement To Revenue 1.23  1.26 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.48  0.45 
Ebit Per Revenue(1.07)(1.12)

Pair Trading with Nektar Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nektar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nektar Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Nektar Stock

  0.53VALN Valneva SE ADRPairCorr
  0.53SRZNW Surrozen WarrantPairCorr
  0.47VIGL Vigil NeurosciencePairCorr
  0.44DMAC DiaMedica TherapeuticsPairCorr
  0.36VERV Verve TherapeuticsPairCorr
The ability to find closely correlated positions to Nektar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nektar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nektar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nektar Therapeutics to buy it.
The correlation of Nektar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nektar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nektar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nektar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Nektar Stock Analysis

When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY